Persistent risk of vascular complications and efficacy of prolonged dual antiplatelet therapy after myocardial infarction
https://doi.org/10.21518/2307-1109-2021-11-2-18-28
Abstract
The article discusses data on the duration of risk retention and the main cause of vascular complications in patients with acute coronary syndrome. Preconditions for prolonged use of dual antiplatelet therapy after myocardial infarction are presented. The authors consider the results of a large, prospective, randomized, placebo-controlled, multinational PEGASUS-TIMI 54 study evaluating the efficacy and safety of the long-term use of acetylsalicylic acid combined with ticagrelor (P2Y12 platelet receptor blocker) in patients with a high risk of thrombotic complications of atherosclerosis in the period from 1 to 3 years after myocardial infarction. The article presents an analysis of optimal approaches to prolonged double antiplatelet therapy after myocardial infarction, taking into account the results of the PEGASUS-TIMI 54 study, which laid the foundation for current clinical guidelines. The PEGASUS-TIMI 54 study demonstrated the benefits of prolonged dual antiplatelet therapy for at least 4 years after myocardial infarction in patients with a high risk of atherothrombotic complications and confirmed the expediency to reduce the dose of ticagrelor from 90 to 60 mg twice daily for 1 year after the onset of the disease to ensure the best balance of efficacy and safety of treatment. The possibility of prolonging double antiplatelet therapy using a combination of ASA and ticagrelor at a dose of 60 mg twice daily for 1 year after myocardial infarction is provided for in the guidelines for medical use of ticagrelor and is enshrined in existing clinical guidelines. Presently, ticagrelor is the only P2Y12 platelet receptor inhibitor approved in the Russian Federation as an adjunct to ASA for the long-term prevention of atherothrombotic cardiovascular events.
About the Author
I. S. Yavelo
National Medical Research Center for Therapy and Preventive Medicine; Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Igor S. Yavelov, Dr. Sci. (Med.), Head of the Department of Fundamental and Clinical Problems of Thrombosis in Non-communicable Diseases, National Medical Research Center for Therapy and Preventive Medicine; Professor of the Department of Therapy and Preventive Medicine, Yevdokimov Moscow State University of Medicine and Dentistry
101990, Moscow, Petroverigskiy Lane, 10
127473, Moscow, Delegateskaya St., Bldg. 1, 20
References
1. Jernberg T., Hasvold P., Henriksson M., Hjelm H., Thuresson M., Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163–1170. https://doi.org/10.1093/eurheartj/ehu505.
2. Fox K.A.A., Carruthers K.F., Dunbar D.R., Graham C., Manning J.R., De Raedt H. et al. Underestimated and underrecognized: the late consequences of acute coronary syndrome (GRACE UK–Belgian Study). Eur Heart J. 2010;31(22): 2755–2764. https://doi.org/10.1093/eurheartj/ehq326.
3. Figueras J., Missorici M., Lidón R.M., Cortadellas J., Soler Soler J. Coincidental annual distribution of first and second acute myocardial infarction. Am J Cardiol. 2002;89(12):1416–1420. https://doi.org/10.1016/s0002-9149(02)02358-5.
4. Stone G.W., Maehara A., Lansky A.J., de Bruyne B., Cristea E., Mintz G.S. et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–235. https://doi.org/10.1056/NEJMoa1002358.
5. Varenhorst C., Hasvold P., Johansson S., Janzon M., Albertsson P., Leosdottir M. et al. Culprit and Nonculprit Recurrent Ischemic Events in Patients With Myocardial Infarction: Data From SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). J Am Heart Assoc. 2018;7(1):e007174. https://doi.org/10.1161/JAHA.117.007174.
6. Kereiakes D.J., Yeh R.W., Massaro J.M., Cutlip D.E., Steg P.G., Wiviott S.D. et al. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016;67(21):2492–2502. https://doi.org/10.1016/j.jacc.2016.03.485.
7. Mauri L., Kereiakes D.J., Yeh R.W., Driscoll-Shempp P., Cutlip D.E., Steg P.G. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–2166. https://doi.org/10.1056/NEJMoa1409312.
8. Yeh R.W., Kereiakes D.J., Steg P.G., Windecker S., Rinaldi M.J., Gershlick A.H. et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015;65(20):2211–2221. https://doi.org/10.1016/j.jacc.2015.03.003.
9. Udell J.A., Bonaca M.P., Collet J.P. Lincoff A.M., Kereiakes D.J., Costa F. et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37(4):390–399. https://doi.org/10.1093/eurheartj/ehv443.
10. Nauta S.T., Deckers J.W., Akkerhuis K.M., van Domburg R.T. Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes. Changes from 1985 to 2008. Diabetes Care. 2012;35(10):2043–2047. https://doi.org/10.2337/dc11-2462.
11. Romain A., Elbaz M., Simon T., Khalife K., Lim P., Ennezat P.V. et al. Prevalence, clinical profile and 3-year survival of acute myocardial infarction patients with and without obstructive coronary lesions: The FAST-MI 2005 registry. Int J Cardiol. 2014;172(1):e247–e249. https://doi.org/10.1016/j.ijcard.2013.12.103.
12. Bhatt D.L., Eagle K.A., Ohman E.M., Hirsch A.T., Goto S., Mahoney E.M. et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350–1357. https://doi.org/10.1001/jama.2010.1322.
13. Bonaca M.P., Bhatt D.L., Cohen M., Steg P.G., Storey R.F., Jensen E.C. et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015;372(19):1791–1800. https://doi.org/10.1056/NEJMoa1500857.
14. Bhatt D.L., Bonaca M.P., Bansilal S., Angiolillo D.J., Cohen M., Storey R.F. et al. Reduction in Ischemic Events with Ticagrelor in Diabetic Patients: From the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2016;67(23):2732–2740. https://doi.org/10.1016/j.jacc.2016.03.529.
15. Magnani G., Storey R.F., Steg G., Bhatt D.L., Cohen M., Kuder J. et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016;37(4):400–408. https://doi.org/10.1093/eurheartj/ehv482.
16. Bonaca M.P., Bhatt D.L., Storey R.F., Steg P.G., Cohen M., Kuder J. et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719–2728. https://doi.org/10.1016/j.jacc.2016.03.524.
17. Bansilal S., Bonaca M., Cornel J.H., Storey R., Bhatt D., Steg Р. et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in patients with prior mi and multivessel coronary disease: insights from the pegasus-timi 54 trial. J Am Coll Cardiol. 2016;67:A2146. https://doi.org/10.1016/S0735-1097(16)32147-7.
18. Bonaca M.P., Bhatt D.L., Steg P.G., Storey R.F., Cohen M., Im K. et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUSTIMI 54. Eur Heart J. 2016;37(14):1133–1142. https://doi.org/10.1093/eurheartj/ehv531.
19. Dellborg M., Bonaca M.P., Storey R.F., Steg P.G., Im K.A., Cohen M. et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):200–206. https://doi.org/10.1093/ehjcvp/pvz020.
20. Bonaca M.P., Bhatt D.L., Oude Ophuis T., Steg P.G., Storey R., Cohen M. et al. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol. 2016;1(4):425–432. https://doi.org/10.1001/jamacardio.2016.1017.
21. Bonaca M.P., Storey R.F., Theroux P., Steg P.G., Bhatt D.L., Cohen M.C. et al. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017;70(11):1368–1375. https://doi.org/10.1016/j.jacc.2017.07.768.
22. Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H. et al. 2017 ESC Guidelines for themanagement of acutemyocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. https://doi.org/10.1093/eurheartj/ehx393.
23. Collet J.-P., Thiele H., Barbato E., Barthélémy О., Bauersachs J., Bhatt D.L. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(14):1289–1367. https://doi.org/10.1093/eurheartj/ehaa575.
24. Valgimigli M., Bueno H., Byrne R.A., Collet J.P., Costa F., Jeppsson A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–260. https://doi.org/10.1093/eurheartj/ehx419.
25. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407–477. https://doi.org/10.1093/eurheartj/ehz425.
26. Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies. With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484.
27. 2020 Clinical practice guidelines for stable coronary artery disease. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;(11):4076. (In Russ.) https://doi.org/10.15829/29/1560-4071-2020-4076.
28. 2020 Clinical practice guidelines for acute st-segment elevation myocardial infarction. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;(11):4103. (In Russ.) https://doi.org/10.15829/1560-4071-2020-4103.
29. Barbarash O.L., Duplyakov D.V., Zateischikov D.A., Panchenko E.P., Shakhnovich R.M., Yavelov I.S. et al. 2020 Clinical practice guidelines for acute coronary syndrome without st segment elevation. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021;(4):4449. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4449.
Review
For citations:
Yavelo I.S. Persistent risk of vascular complications and efficacy of prolonged dual antiplatelet therapy after myocardial infarction. Aterotromboz = Atherothrombosis. 2021;11(2):18-28. (In Russ.) https://doi.org/10.21518/2307-1109-2021-11-2-18-28
Views:
688
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 